Лист за преговор: Medicines: History, Regulation, Discovery

Medicine - Definitions, History, and Regulation

Exam-Oriented Revision Sheet

1. 📌 Essentials

• Medicine: Substance with curative or preventive properties.
• Phology: Study of drugs' discovery, effects, and use.
• Pharmacopée: Official reference book defining raw material standards.
• Key historical milestones: Sumér tablets, Egyptian papyrus, Hippocrates, quinine, penicillin, chlorpromazine.
• Drug development phases: Preclinical (safety), clinical (efficacy), post-marketing surveillance.
• Regulatory bodies: ANSM (France), EMA (Europe); approval via AMM valid 5 years.
• Classification systems: ATC hierarchical system; forms include tablets, solutions, creams, injections.
• Sources of drugs: Natural (plants, animals, minerals), synthetic, biotechnological.
• Discovery methods: Observation, chance, error, rational design.
• Evidence levels: Meta-analyses, large RCTs (high); case series (low).
• Pharmacovigilance: Ongoing safety monitoring post-approval.

2. 🧩 Key Structures & Components

• Medicines: Active substances + excipients.
• Pharmacopée: Reference standards for purity and quality.
• Drug sources:
  • Plants (e.g., willow bark)
  • Animals (e.g., insulin)
  • Minerals (e.g., arsenic compounds)
  • Synthetic chemicals (e.g., aspirin)
  • Biotechnological products (e.g., monoclonal antibodies)
• Drug forms: Tablets, capsules, solutions, creams, injections.
• Routes of administration: Oral, subcutaneous, intramuscular, intravenous.
• Regulatory agencies: ANSM (France), EMA (Europe).
• Classification systems:
  • Anatomical (e.g., nervous system)
  • Therapeutic (e.g., antibiotics)
  • Chemical (e.g., benzodiazepines)
  • ATC code: hierarchical, e.g., N05BA01 (diazepam).

3. 🔬 Functions, Mechanisms & Relationships

• Discovery: Based on observation, chance, error, or rational design targeting specific biological pathways.
• Development:
  • Preclinical: safety, toxicity tests.
  • Clinical: efficacy, safety in humans (Phases I-IV).
• Mechanism of action:
  • Active principles bind to receptors, enzymes, or pathways.
  • Excipients aid stability, absorption, or administration.
• Regulation:
  • Approval (AMM) requires demonstration of safety, efficacy, and quality.
  • Post-marketing surveillance detects adverse effects.
• Hierarchy:
  • Natural/biological sources → Active ingredient → Formulation → Route of administration → Therapeutic effect.
• Evidence flow:

Discovery → Preclinical → Clinical trials (Phases I-IV) → Approval → Post-marketing surveillance

4. 📊 Comparative Table

Item	Key Features	Notes / Differences
Natural sources	Plants, animals, minerals	Traditional remedies, biotechnological advances
Synthetic sources	Semi-synthetic, total synthesis	Controlled, scalable production
Biological medicines	Derived from organisms (e.g., insulin, antibodies)	Complex structure, biosimilars
Prodrugs	Inactive compounds activated in vivo	Improve bioavailability or targeting
Routes of administration	Oral, injectable, topical	Affects absorption and onset of action

5. 🗂️ Hierarchical Diagram (ASCII)

Medicines
 ├─ Natural Sources
 │    ├─ Plants
 │    ├─ Animals
 │    └─ Minerals
 ├─ Synthetic Drugs
 │    ├─ Semi-synthetic
 │    └─ Total synthesis
 └─ Biological & Biotechnological
      ├─ Insulin
      ├─ Monoclonal antibodies
      └─ Biosimilars

6. ⚠️ High-Yield Pitfalls & Confusions

• Confusing pharmacopée (reference book) with pharmacology (study).
• Mistaking natural remedies as inherently safe; many have toxicity.
• Overlooking the importance of regulatory approval (AMM) for safety and efficacy.
• Assuming all drugs are synthetic; many are natural or biotechnological.
• Misunderstanding prodrugs: inactive until metabolized.
• Confusing classification systems: chemical vs. therapeutic vs. anatomical.
• Ignoring post-marketing surveillance as a critical safety step.
• Overestimating evidence from small case series; high-level evidence needed.
• Mixing up discovery methods: chance vs. rational design.
• Assuming biosimilars are identical to original biologics (they are similar but not identical).

7. ✅ Final Exam Checklist

• Define medicine, pharmacology, and pharmacopée.
• Summarize key historical milestones in drug development.
• Describe the phases of clinical trials and their purpose.
• Explain the regulatory process for drug approval (AMM).
• Understand the ATC classification system and drug forms/routes.
• List natural and synthetic sources of drugs.
• Describe discovery methods: observation, chance, error, rational design.
• Recognize high vs. low evidence in clinical research.
• Identify main sources of drug information (VIDAL, PubMed, agencies).
• Understand post-marketing pharmacovigilance importance.
• Differentiate between biological, biosimilar, and chemical medicines.
• Know the concept of prodrugs and their purpose.
• Recall the main historical milestones: Hippocrates, quinine, penicillin, chlorpromazine.
• Be aware of the regulatory bodies (ANSM, EMA) and their roles.
• Comprehend the hierarchical organization from source to therapeutic effect.
• Recognize common pitfalls and confusions in drug classification and regulation.

This revision sheet condenses core concepts, structures, and relationships for effective exam preparation on medicines, their history, development, and regulation.